Search results
Regeneron CEO Leonard Schleifer sells over $35 million in company stock By Investing.com
Investing.com· 3 hours agoRegeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ:REGN) has reported several transactions by its...
Examining the Potential Price Growth of Regeneron Pharmaceuticals, Inc.
Knox Daily· 19 hours agoBernstein initiated its Regeneron Pharmaceuticals, Inc. [REGN] rating to an Outperform in a research note published on March 12, 2024; the price target ...
Regeneron shares rise on Evercore ISI Outperform rating By Investing.com
Investing.com· 2 days agoOn Monday, Evercore ISI initiated coverage on Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc....
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Merit Financial Group LLC
ETF DAILY NEWS· 7 days agoThe firm owned 327 shares of the biopharmaceutical company’s stock after selling 379 shares during the quarter. Merit Financial Group LLC’s holdings in Regeneron& ...
... Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years - Regeneron...
Benzinga· 1 day agoRegeneron Pharmaceuticals REGN has outperformed the market over the past 10 years by 2.01% on an annualized basis producing an average annual return of 12.78%. Currently, ...
Qsemble Capital Management LP Purchases Shares of 239 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
ETF DAILY NEWS· 2 days ago:REGN – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 239 shares of the biopharmaceutical company ...
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) large institutional owners must be happy as stock...
Simply Wall St. via Yahoo Finance· 6 days agoWhen multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'....
Bayer (BAYRY) Q1 Earnings Fall Y/Y on Lower Product Sales
Zacks via Yahoo Finance· 2 days agoBayer's (BAYRY) Q1 earnings and sales decline year over year due to a fall in volumes for...
Earnings call: Intellia Therapeutics reports robust Q1 progress By Investing.com
Investing.com· 6 days agoIntellia Therapeutics (NASDAQ: NASDAQ:NTLA) has made significant progress in the first quarter of...
Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates
Zacks· 6 days agoIntellia's (NTLA) earnings and revenues surpass estimates in the first quarter of 2024. The company provides developmental and regulatory updates on its pipeline candidates. Stock rises.